---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-100470"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2026-08-25T10:01:24+00:00"
generated_at: "2026-08-25T10:05:07.445667+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio sets scheme exchange ratio at 0.111; merger with Clywedog to close Sept 3

## Summary
- Scheme exchange ratio set at 0.111, ensuring Topco stock price meets Nasdaq minimum listing requirement.
- Scheme expected effective Sept 3, 2026; BRNS ADSs to halt trading before market open that day.
- Court hearing for scheme set for Sept 1, 2026 at Royal Courts of Justice, London.
- After close, Topco renamed Clywedog Therapeutics Holdings, Inc., trading as CLYD on Nasdaq.
- Company to delist ADSs from Nasdaq and file Form 15 to suspend reporting obligations.

## SEC filing metadata
- accession: 0001104659-26-100470
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2026-08-25T10:01:24+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465926100470/0001104659-26-100470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465926100470/tm2623930d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-100470
- JSON: https://secwatch.observer/filing/0001104659-26-100470.json
- Plain text: https://secwatch.observer/filing/0001104659-26-100470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.